Related Experiment Video
Updated: Jun 9, 2025

05:38
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
Published on: January 7, 2019
17.8K
Shisandra Decoction Alleviates Parkinson's Disease Symptoms in a Mouse Model Through PI3K/AKT/mTOR Signalling Pathway
Yawen Pan1, Mojinzi Chen2, Lulu Pan3
1Wenzhou TCM Hospital of Zhejiang Chinese Medical University, Wenzhou, 325000, People's Republic of China.
Neuropsychiatric Disease and Treatment
|October 28, 2024
Summary
Schisandra Decoction (Sch D) improves motor function and neuroprotection in a Parkinson
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor deficits and the accumulation of alpha-synuclein (α-syn).
- The mammalian target of rapamycin (mTOR) signaling pathway plays a crucial role in cellular processes, including autophagy, which is implicated in PD pathogenesis.
Purpose of the Study:
- To investigate the neuroprotective effects of Schisandra Decoction (Sch D) in a mouse model of Parkinson's disease (PD).
- To elucidate the underlying mechanisms of Sch D's action, focusing on the PI3K/AKT/mTOR signaling pathway and its influence on autophagy and α-synuclein aggregation.
Main Methods:
- Establishment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse model.
- Assessment of motor function using pole climbing, rotarod, and open field tests.
- Quantification of neuroprotection markers (Tyrosine hydroxylase - TH, α-synuclein) and autophagy markers (PTEN, PI3K, Akt, p-Akt, mTOR, p-mTOR, p70s6K, p62, LC3II/I) via immunohistochemistry, RT-PCR, and Western blotting.
Main Results:
- Sch D treatment significantly improved motor function in PD mice, evidenced by reduced pole climbing time and increased rotarod duration.
- Sch D administration led to increased TH protein levels and enhanced α-synuclein clearance in the brains of PD mice.
- Sch D reversed MPTP-induced alterations in the PI3K/AKT/mTOR pathway, including reduced PTEN, increased PI3K/Akt/mTOR signaling, and normalized LC3II/I and p62 levels, indicating autophagy inhibition.
Conclusions:
- Schisandra Decoction (Sch D) demonstrates significant neuroprotective effects in an MPTP-induced Parkinson's disease mouse model.
- Sch D improves motor function and reduces α-synuclein aggregation, potentially through the inhibition of autophagy via the PI3K/AKT/mTOR pathway.
- The findings suggest that Sch D's neuroprotective properties may be linked to its ability to modulate autophagy and potentially exert antioxidant effects, warranting further investigation into its antioxidant capacity.
Related Concept Videos
Parkinson's Disease: Treatment
227
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
227
Parkinson's Disease: Overview
486
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
486

